The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I guess you could use the Doc D method of intervention. Wait until theyâre in ICU and theyâre definitely your patients.
By that time they have life changing consequences to their lungs, heart, kidneys etc and May die anyway and you have an ongoing health service problem in the 10âs to 100âs of thousands of pounds if they survive.
Or you could use precision medicine to identify those patients likely to end up in ICU and give them early intervention and save billions in health costs.
Of course you also need to consider the next pandemic. This one cost the USA 16 trillion and the U.K. 450 billion. So itâs probably a good idea to have a broad spectrum antiviral in your cupboard
Dr Phillip Monk joined Synairgen in October 2006 as Head of Bioscience Development and was appointed to the Board as Chief Scientific Officer in September 2009.
Phillip was previously Director of the Respiratory and Inflammation Biology group at Cambridge Antibody Technology (âCATâ)
focussed on harnessing the exploitation of the human genome.
He seems quite qualified to work on precision medicine
Prof Djukanovic is a professor of medicine at the University of Southampton's Faculty of Medicine, and was director of the Southampton Centre for Biomedical Research (SCBR) from November 2011 to April 2017. He's the lead of the respiratory and critical care theme within the NIHR Southampton Biomedical
Research Centre (BRC), a centre of excellence funded by the National Institute for Health Research
Prof Djukanovic also heads a multi-disciplinary team whose objective is to find valuable biomarkers of asthma and (COPD). This work has been funded previously by the US funding body, the National Institutes of Health (NIH), and more recently by the Innovative Medicines Initiative (IMI) grant to study severe asthma (âŹ23 million). This involves a consortium of academic centres and pharmaceutical companies in a programme led by the Southampton NIHR Respiratory BRU, the Respiratory BRU at the National Heart and Lung Institute (NHLI) in London and the University of Amsterdam.
He seems quite qualified to work on Precision Medicine
It seems they have more specialists knowledge than some give them credit.
They produced a whole presentation on the subject
https://synairgen.ams3.digitaloceanspaces.com/230629-Synairgen-AGM-2023_FINAL.pdf
Precision Medicine
Thereâs a who field of scientific endeavour around it which is fascinating. At least for some of us it is.
FDA
âMost medical treatments are designed for the "average patient" as a one-size-fits-all-approach, which may be successful for some patients but not for others. Precision medicine, sometimes known as "personalized medicine" is an innovative approach to tailoring disease prevention and treatment that takes into account differences in people's genes, environments, and lifestyles. The goal of precision medicine is to target the right treatments to the right patients at the right timeâ
I guess the whole field of biomarker identification and
patient stratification is pointless.
Doctors should just wait for people to appear on a ventilator and then they know theyâre ill.
You should publish a paper on the subject Doc D
âOur patients are identifiable in the hospital without the clever modern profiling asays we seem to be waiting for. Age, co-morbitiiesââŠâŠ
Well Iâm dying to ask Doc D
Tell us the patient profile then for someone who will become severely ill compared to someone who wonât?
Do you have some published scientific article on your answer?
When is a small number of patients a big number ?
The Need
Viruses that cause severe respiratory infections (VRIs) lead to the hospitalisation of more than 3 million people in the US alone each year.
There are currently no broad-spectrum antivirals approved for use in patients who become hospitalised with these sRVIs including SARS-CoV-2, complicated influenza, RSV, adenovirus, parainfluenza and rhinoviruses.
I wonder what the number of patients is if you include Europe. The Far east, the Middle East.
Commercially viable marketâŠ..absolutely
Sprinter data was very strong âŠâŠ.
IN THE RIGHT COHORT OF PATIENTS, IF YOU CAN IDENTIFY THEM.
If only you would listen !
The reason no one has picked us up is likely because until we can demonstrate we know how to select the right cohort of patients, we have an expensive drug with no way of accurately assigning patients.
These are not excuses, these are the scientific facts and thatâs why the company are producing further trials.
Sadly you seem to have no interest in this truth.
âIf only weâd gone back to COPD it would be complete nowâ
If only people would read the science and understand trials they wouldnât make these remarks
Go and look at
Verona Pharma Ensifentrine or
Sanofi Dupixent.
Take a good look at the number of trials and particularly the patient trial size, and the cost of running them.
2 to 3 times the size of our Sprinter trial.
Then compare it to our COPD p2 thatâs P2 not a P3 of 109 patients.
Then perhaps you will realise how wrong your comments are, but quite honestly I doubt it.
Ghia
lol
I did pull the threads to one of the worst presentations on YouTube Iâve seen by someone with a tiny amount of experience and only 34 views.
10 of which are probably people on this board because you posted the link.
Unless you have something a little more substantial I shall file this under tangentially interesting
Iâve seen the study Ghia it dates back to sampling TopMd did 4 years ago in 2020.
Iâm just surprised nothing has come of it in collaboration with BP etc since then.
Given the expertise Synairgen have in-house shown by them being chosen as a preferred partner for Southampton and JnJ.m and having done previous analysis of their own trials. Do Synairgen even need an external partner for this work in their trials?
One thing doesnât make sense regarding TopMd
The EU Dragon project concluded last year. They appear to be a very small private company at least according to their published accounts.
There only collaboration seems to be through Southampton, with very little published scientific study work outside of that collaboration.
Youâd therefore expect them to be using a high profile J&J Southampton Universal trial to promote themselves but no mention of any collaboration.
Youâd think theyâd be promoting working with Synairgen on these future trials. After all Synairgen has had quite a good profile during COVID in the U.K. and US and there are clear links between what Synairgen are trying to achieve and the biomarker platform analysis TopMd are doing. But again no mention by either party?
TopMdâs biomarker pathway platform has been around since 2019 so itâs hardly a trade secret.
Interim RNS RM
âWe hope to maximise the benefits of treatment with SNG001 by targeting patients most likely to respond to treatment by applying both existing and new technologies for patient selection in our next trials of SNG001. This will enable us to focus on the most appropriate patients which will ultimately lead to trials of SNG001 in more targeted, but still large, patient populations at high risk of severe outcomes.â
We know Synairgen are using their own data. Data from Universal and the wording ânew technologiesâ
Where these will come from, other than the mention of Casanova, we donât know.
Synairgen are highly invested in patient stratification for our next trials and that can only be good news for a positive outcome.
For those who think itâs taking too long. Read the science on this subject.
Scientists have been investigating why some patients suffer severe outcomes whilst others donât ever since SARS COVID arrived. Itâs a highly complex area, not as easy as some on this board would suggest.
https://www.mdpi.com/1422-0067/23/16/9161
Combining Deep Phenotyping of Serum Proteomics and Clinical Data via Machine Learning for COVID-19 Biomarker Discovery
Ghia
I didnât say it wasnât relevant. In fact I said the opposite, that they are both looking at the same area. But to be fair dozens of other companies are too.
Not the best YouTube example, it makes Phillip Monk sound highly interesting by comparison and thatâs not easy to do. But from 12 mins on you get the impression that this is ongoing research thatâs interesting, sadly rather poorly presented, but just a continuation (as even the speaker says) of work in this field.
You original post had a flare for the dramatic, as though weâd all been missing some great Synairgen / TooMd clue. I donât see it evidenced in what youâve provided in the links
They work in the same postcode, share a very similar synergy in the science but Synairgen havenât mentioned them nor they Synairgen and the same applies to the Universal study. As I said previously great company, great science, but are they linked in our future trials is just pure speculation. Unless you have some magic bullet that youâve not shared?
Links between Southampton and TopMd
Dragon is nothing new itâs an EU program dating from early COVID funding research companies like TopMd but also many others. No links to Synairgen and Dragon
https://www.southampton.ac.uk/research/highlights/helping-diagnose-treat-covid-19-more-quickly
TopMD are a spin off from Southampton
Working in precision medicine and molecular phenotyping and patient stratification.
All the things Synairgen are interested in and also working on. But so are probably 50 other companies.
Itâs interesting, itâs possible they are working together but we have no evidence they are. They could be working with Universal and JnJ but again we have no evidence. Their science is first rate.
Https://biolres.biomedcentral.com/articles/10.1186/s40659-023-00482-x
âAlpha-synuclein dynamics bridge Type-I Interferon response and SARS-CoV-2 replication in peripheral cellsâ
In endothelial cells, SNCA loss-of-function promotes age-related dysfunction going along with hyper-inflammation and elevated blood pressure, which suggests a key role of α-syn in maintaining vascular integrity
SARS-CoV-2-induced reduction of α-syn multimerization was reversed by IFN-ÎČ, which significantly increased total α-syn mostly by promoting multimeric species to rescue α-syn multimer:monomer ratio in SARS-CoV-2-infected cells
These data suggest that the antiviral effect of IFN-ÎČ is associated both with stimulation of endogenous α-syn synthesis, and promotion of α-syn multimerization to counterbalance an excess of α-syn monomers.